Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Saturday's Featured Story A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHAuthor: Nathan Reiff. Publication Date: 2/12/2026. 
Key Points - AstraZeneca, Edwards Lifesciences, and Zimmer Biomet all reported earnings on the same day, but with vastly different results.
- Of these, AstraZeneca's impressive oncology medicine sales growth stands out, having driven significant top-line growth.
- Edwards and Zimmer both saw notable successes in the latest quarter, but also face sizable challenges.
More than just a financial check-up, earnings for companies in the healthcare sector offer investors a window into a firm's pipeline and development progress. Even well-established, stable firms can surprise with growth after the release of a new blockbuster drug or medical device, and earnings season gives management an opportunity to provide insight beyond regulatory approval announcements. When multiple healthcare companies report on the same day, investors can face a busy stream of news and must quickly decide how to react. On Feb. 10, 2026, three major names in the sector—AstraZeneca (NASDAQ: AZN), Edwards Lifesciences (NYSE: EW), and Zimmer Biomet (NYSE: ZBH)—reported full-year and Q4 2025 results. Below are the highlights and takeaways for healthcare investors planning their next moves. AstraZeneca Firms Up Cancer Business in a Strong Overall Quarterly Performance Watch Now! Porter Stansberry & Luke Lango join forces to unveil:
The Three Titanic Forces Converging To Unleash A New 1776 Moment
"We have never seen wealth created at this size and speed" MIT Researcher Click here for the stocks to buy and sell now U.K.-based pharma giant AstraZeneca ended 2025 by cementing its position as a go-to provider of cancer medicines, which accounted for about 44% of product sales in the quarter. Sales of oncology drugs such as Imfinzi and Enhertu grew as much as 48% year-over-year (YOY), helping to drive total revenue up 8.6% to $58.7 billion for the year. After-tax profits rose alongside revenue, climbing to $10.2 billion from $7.0 billion in the prior-year quarter, prompting the company's board to declare a second interim dividend that is 7 cents higher than last year's. Investors also have more to watch as the company advances dozens of drugs through development: management said 20 Phase 3 readouts are expected in 2026. AstraZeneca expects solid increases in both total revenue and core earnings per share (EPS) for full-year 2026. In the hours after its strong earnings announcement, AZN shares rose nearly 3%. Although 10 of 11 analysts rate AZN a Buy or equivalent, Wall Street has raised valuation questions—the consensus price target of $95.75 implies downside of roughly 51% from current levels. TAVR Momentum Fuels Edwards Sales Growth, Though Investors Should Note Earnings and Margin Limitations Edwards makes replacement heart valves and related surgical devices, along with monitoring systems. The firm's Q4 2025 results were largely positive, including 13.3% YOY sales growth driven by continued transcatheter aortic valve replacement (TAVR) momentum and uptake of the latest SAPIEN valve iteration. However, adjusted EPS missed analyst expectations and gross profit margin fell 0.8 percentage points YOY. Despite the mixed metrics for the quarter, Edwards remains confident it can meet its prior 2026 outlook, which calls for sales growth of 8%–10% YOY and EPS between $2.90 and $3.05. EW shares climbed above $80 in after-hours trading—about 4% above the prior close—following the announcement. About two-thirds of analysts covering EW rate the shares a Buy, and the consensus price target implies upside of roughly 25% to $96.77. Orthopedic Demand Remains High, But Zimmer Faces Some Headwinds Zimmer Biomet, a maker of joint replacement systems and orthopedic implants, saw its shares rise more than 3% after reporting EPS of $2.42, four cents above consensus, and revenue of $2.2 billion—up almost 11% YOY and slightly ahead of expectations. Strong demand for Zimmer's orthopedic products supported both top- and bottom-line growth. Zimmer is also shifting focus more heavily toward the U.S., which represents nearly 60% of its business. With insured patient utilization rising, near-term demand for Zimmer's products should remain elevated. That said, the company expects tariffs to be a headwind that could weigh on EPS and revenue in 2026. Management issued conservative guidance in the latest earnings report, forecasting adjusted EPS of $8.30–$8.45 and free cash flow improvement of 8%–10%. Analysts remain divided on Zimmer: the consensus rating is Hold, even though the average price target implies roughly 15% upside.
| 
